BEIJING, China, May 16, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to build an integrated biologics development, clinical and commercial manufacturing center in the city of Shijiazhuang, capital of Hebei province in northern China.
The new state-of-the-art biologics center will include process development labs, clinical manufacturing facility (MFG9) with 5,000 L bioreactor capacity and commercial manufacturing facility (MFG8) with 48,000 L bioreactor capacity which will be built to meet cGMP standards of the United States, the European Union, and China. Besides serving global clients, the new integrated center will also support Marketing Authorization Holder (MAH) system in China and address urgent needs of Chinese partners. Initial phase of the center will be operational in 2020.
"We are very pleased to establish the largest biologics center in northern China, which will enable local companies to more effectively develop and manufacture biologics and in the meantime provide a robust supply chain network for our global clients. This expansion will allow us great access to local talents, markets and government support," said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. "With this investment and current 161 biologics programs that WuXi Biologics will manufacture, we will quickly and cost effectively expand our manufacturing capacity to meet our partners' needs and become one of the global CMO leaders."
.svg)
